summit is a uk company focused on the discovery and development of novel drug candidates to treat areas of high unmet medical need. our strategy focuses on two therapy areas: duchenne muscular dystrophy, a fatal genetic muscle wasting disease and the infectious disease caused by the bacteria c. difficile.
![Summit Therapeutics logo](/files/LOGO/1599298-SMMT.png)
Company profile
Ticker
SMMT
Exchange
Website
CEO
Robert W. Duggan
Employees
Incorporated
Location
Fiscal year end
Sector
Industry (SIC)
Former names
Summit Therapeutics plc, Summit Corp plc
SEC CIK
Corporate docs
Subsidiaries
Summit (Oxford) Limited • Discuva Limited • Summit Therapeutics Sub Inc. • Summit Therapeutics Limited • Summit International Holdings Limited • Summit Therapeutics Global LLC ...
SMMT stock data
Latest filings (excl ownership)
8-K
Entry into a Material Definitive Agreement
27 Jun 24
D
$200.00 mm in equity, sold $200.00 mm, 2 investors
18 Jun 24
8-K
Departure of Directors or Certain Officers
17 Jun 24
DEFA14A
Additional proxy soliciting materials
13 Jun 24
8-K
Entry into a Material Definitive Agreement
3 Jun 24
8-K
Presented by Dr. Li Zhang, ASCO 2024
3 Jun 24
8-K
Other Events
30 May 24
8-K
Other Events
24 May 24
8-K
Entry into a Material Definitive Agreement
13 May 24
424B5
Prospectus supplement for primary offering
13 May 24
Transcripts
SMMT
Earnings call transcript
2024 Q1
1 May 24
SMMT
Earnings call transcript
2023 Q4
20 Feb 24
SMMT
Earnings call transcript
2023 Q3
7 Nov 23
SMMT
Earnings call transcript
2023 Q2
9 Aug 23
SMMT
Earnings call transcript
2023 Q1
11 May 23
SMMT
Earnings call transcript
2022 Q4
9 Mar 23
SMMT
Earnings call transcript
2018 Q4
27 Mar 19
SMMT
Earnings call transcript
2018 Q2
20 Sep 18
SMMT
Earnings call transcript
2017 Q4
11 Apr 18
Financial summary
Quarter (USD) | Mar 24 | Dec 23 | Sep 23 | Jun 23 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 23 | Dec 22 | Dec 21 | Dec 20 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 61.61 mm | 61.61 mm | 61.61 mm | 61.61 mm | 61.61 mm | 61.61 mm |
Cash burn (monthly) | 3.27 mm | 779.83 k | 14.13 mm | 9.57 mm | 10.04 mm | 7.81 mm |
Cash used (since last report) | 12.65 mm | 3.02 mm | 54.64 mm | 37.02 mm | 38.84 mm | 30.21 mm |
Cash remaining | 48.96 mm | 58.60 mm | 6.97 mm | 24.59 mm | 22.77 mm | 31.40 mm |
Runway (months of cash) | 15.0 | 75.1 | 0.5 | 2.6 | 2.3 | 4.0 |
Institutional ownership, Q1 2024
10.5% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 102 |
Opened positions | 41 |
Closed positions | 10 |
Increased positions | 29 |
Reduced positions | 19 |
13F shares | Current |
---|---|
Total value | 198.72 bn |
Total shares | 73.50 mm |
Total puts | 29.90 k |
Total calls | 103.30 k |
Total put/call ratio | 0.3 |
Largest owners | Shares | Value |
---|---|---|
Zanganeh Maky | 24.89 mm | $37.83 mm |
BLK Blackrock | 9.82 mm | $40.67 bn |
STT State Street | 8.11 mm | $33.59 bn |
FMR | 7.97 mm | $33.01 bn |
Vanguard | 7.27 mm | $30.09 bn |
Geode Capital Management | 3.15 mm | $13.05 bn |
NTRS Northern Trust | 1.07 mm | $4.44 bn |
MS Morgan Stanley | 692.54 k | $2.87 bn |
GS Goldman Sachs | 680.60 k | $2.82 bn |
Rafferty Asset Management | 650.29 k | $2.69 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
27 Jun 24 | Jeff Huber | Stock Option Common Stock | Grant | Acquire A | No | No | 7.87 | 17,883 | 140.74 k | 217,883 |
27 Jun 24 | Jeff Huber | Stock Option Common Stock | Grant | Acquire A | No | No | 7.87 | 200,000 | 1.57 mm | 200,000 |
11 Apr 24 | Ronaghi Mostafa | Stock Option Common Stock | Grant | Acquire A | No | No | 4.03 | 25,315 | 102.02 k | 225,315 |
11 Apr 24 | Ronaghi Mostafa | Stock Option Common Stock | Grant | Acquire A | No | No | 4.03 | 200,000 | 806.00 k | 200,000 |
News
10 Health Care Stocks Whale Activity In Today's Session
26 Jul 24
IQVIA Posts Upbeat Earnings, Joins Terex, Reddit And Other Big Stocks Moving Higher On Monday
22 Jul 24
XPeng & QuantumScape Are Among Top 11 Mid Cap Stocks That Performed Well Last Week (July 7-July 13): Details
14 Jul 24
10 Health Care Stocks With Whale Alerts In Today's Session
7 Jun 24
Five Below Posts Weak Q1 Results, Joins Sprinklr, Dorian LPG And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
6 Jun 24
Press releases
Summit Therapeutics and MD Anderson Announce Strategic Collaboration to Accelerate Development of Ivonescimab
25 Jul 24
Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
3 Jul 24
Summit Raises $200 Million; Also Expands License Territories for Ivonescimab
3 Jun 24
Ivonescimab Manuscript for HARMONi-A Clinical Trial Results Published in JAMA
1 Jun 24
Ivonescimab in Combination with Chemotherapy Approved in China by NMPA for 2L+ EGFRm NSCLC based on HARMONi-A Clinical Trial: Positive Trend Observed in Overall Survival towards Ivonescimab Plus Chemotherapy
31 May 24